Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Resistance to therapies.

Bücher zum Thema „Resistance to therapies“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Bücher für die Forschung zum Thema "Resistance to therapies" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Bücher für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Xavier, Ana C., und Mitchell S. Cairo, Hrsg. Resistance to Targeted Therapies in Lymphomas. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-24424-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ling, Silvia CW, und Steven Trieu, Hrsg. Resistance to Targeted Therapies in Multiple Myeloma. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-73440-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Villanueva, Augusto, Hrsg. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56197-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Prosperi, Jenifer R., Hrsg. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Tivnan, Amanda, Hrsg. Resistance to Targeted Therapies Against Adult Brain Cancers. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46505-0.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Szewczuk, Myron R., Bessi Qorri und Manpreet Sambi, Hrsg. Current Applications for Overcoming Resistance to Targeted Therapies. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Ferreri, Andrés J. M., Hrsg. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75184-9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Scardino, Peter T. Targeted Therapies for Castration-Resistant Prostate Cancer. Unitec House, 2 Albert Place, London N3 1QB, UK: Future Medicine Ltd, 2011. http://dx.doi.org/10.2217/9781780840109.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Michael, Neenan, Hrsg. Working with resistance in rational emotive behaviour therapy: A practitioner's guide. London: Routledge, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
11

Targeted Therapies: Mechanisms of Resistance. Humana, 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
12

Targeted therapies: Mechanisms of resistance. New York: Humana Press, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
13

Gioeli, Daniel. Targeted Therapies: Mechanisms of Resistance. Humana Press, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
14

Cairo, Mitchell S., und Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer International Publishing AG, 2020.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
15

Cairo, Mitchell S., und Ana C. Xavier. Resistance to Targeted Therapies in Lymphomas. Springer, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
16

Lasfar, Ahmed, Andrew Zloza, Karine A. Cohen-Solal und Murugabaskar Balan, Hrsg. Tumor Microenvironment and Resistance to Current Therapies. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-283-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
17

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2017.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
18

Ling, Silvia, und Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2021.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
19

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2017.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
20

Prosperi, Jenifer R. Resistance to Targeted Therapies in Breast Cancer. Springer, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
21

Villanueva, Augusto. Resistance to Molecular Therapies for Hepatocellular Carcinoma. Springer, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
22

Ling, Silvia Cw, und Steven Trieu. Resistance to Targeted Therapies in Multiple Myeloma. Springer International Publishing AG, 2022.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
23

Szewczuk, Myron R., Bessi Qorri und Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
24

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer International Publishing AG, 2019.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
25

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2016.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
26

Szewczuk, Myron R., Bessi Qorri und Manpreet Sambi. Current Applications for Overcoming Resistance to Targeted Therapies. Springer International Publishing AG, 2020.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
27

Ferreri, Andrés J. M. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Springer, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
28

Tivnan, Amanda. Resistance to Targeted Therapies Against Adult Brain Cancers. Springer, 2018.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
29

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer New York, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
30

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
31

Bonavida, Benjamin. Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance. Springer London, Limited, 2013.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
32

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Springer International Publishing AG, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
33

Cappuzzo, Federico. Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Adis International, Limited, 2015.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
34

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne und Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.

Der volle Inhalt der Quelle
Annotation:
Hormone therapy describes the role of hormones in the growth of a variety of cancers, and the therapeutic effects of manipulation of hormone levels in these diseases. Sex hormones stimulate the growth of breast and prostate cancers, many of which respond to surgical removal of the hormone-secreting gonad. Pharmacological measures to deliver hormone therapy in these diseases include luteinising hormone releasing hormone (LHRH) agonists and antagonists, inhibitors of sex hormone synthesis, and inhibitors of hormone-receptor binding. These treatments have established benefits in both in the control of advanced disease and the adjuvant therapy of early-stage disease. The pros and cons of combination hormone therapy are discussed. Resistance to hormone therapy may be primary or acquired, and the likely mechanisms are described.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
35

Fraziano, Maurizio, Roberto Nisini, Gian Maria Rossolini und Marco Rinaldo Oggioni, Hrsg. Exploiting Novel Combined Host- and Pathogen-Directed Therapies for Combating Bacterial Multidrug Resistance. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88966-307-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
36

Ensell, Alden. Insulin Resistance Diet - Combat Pcos Problems, Daily Food Plans, Proper Lifestyle and Tasty Recipes: Pcos and Natural Therapies. Independently Published, 2021.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
37

Poma, Alessandro, und Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
38

Poma, Alessandro, und Loris Rizzello. Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance. Elsevier, 2022.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
39

Howland, Robert H. Multidisciplinary Treatments and Medications for Depressive Disorders and Comorbidity. Herausgegeben von C. Steven Richards und Michael W. O'Hara. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780199797004.013.008.

Der volle Inhalt der Quelle
Annotation:
Compared with episodic depression, chronic depression and treatment resistant depression have higher rates of comorbidity, more persistent social and vocational disability, an increased risk of suicide, greater medical morbidity and mortality, and greater health care utilization and costs. A large number of antidepressant medications and other psychotropic drugs, depression-focused psychotherapies, and neuromodulation therapies are available for the treatment of depression. Many drugs or psychotherapies are used for the treatment of other psychiatric disorders or medical conditions, and they should be considered relevant when these comorbidities exist with depression. Selecting treatments for depression must take into account the clinical implications of the presence of any comorbidities. Because comorbidity is associated with depressive chronicity and treatment resistance, various approaches to treating chronic depression or TRD have been investigated. Treating depressed patients with comorbid psychiatric, personality, or medical disorders is a clinical challenge that requires effective multidisciplinary collaboration.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
40

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology Books, 2024.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
41

Murrough, James. Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation. Elsevier Science & Technology, 2024.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
42

Stafstrom, Carl E. Alternative Therapies for Epilepsy. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0046.

Der volle Inhalt der Quelle
Annotation:
Up to one third of patients with epilepsy suffer from seizures that are refractory to medications. For these patients, many of whom are not surgical candidates, dietary therapies provide a promising alternative. The best known dietary therapy is the ketogenic diet, which was developed in the 1920s; newer variants of the ketogenic diet, such as the medium-chain triglyceride diet, modified Atkins diet, and low glycemic index treatment, afford excellent seizure control with fewer dietary restrictions. Together, dietary approaches offer drug-resistant patients hope for seizure reduction and an improved quality of life.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
43

Fu, Caiyun, Yongchuan Gu, Hong Zhu, Wen Zhou und Fanfan Zhou, Hrsg. Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-428-2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
44

Kreit, John W. Severe Obstructive Lung Disease. Herausgegeben von John W. Kreit. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190670085.003.0013.

Der volle Inhalt der Quelle
Annotation:
Although chronic obstructive lung disease, asthma, bronchiectasis, and bronchiolitis have very different causes, clinical features, and therapies, they share the same underlying pathophysiology. They are referred to as obstructive lung diseases because airway narrowing causes increased resistance and slowing of expiratory gas flow. Mechanical ventilation of patients with severe obstructive lung disease often produces two problems that must be recognized and effectively managed: over-ventilation and dynamic hyperinflation. Severe Obstructive Lung Disease reviews these two major adverse consequences of mechanical ventilation in patients with severe air flow obstruction. The chapter explains how to detect and correct both of these problems and provides guidelines for managing patients with respiratory failure caused by severe obstructive lung disease.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
45

León-Buitimea, Angel, Jose Ruben Morones-Ramirez, Jason H. Yang und Rafael Peña-Miller, Hrsg. Facing the Upcoming of Multidrug-Resistant and Extensively Drug-Resistant Bacteria: Novel Antimicrobial Therapies (NATs). Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-653-9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
46

Kessler, Sudha Kilaru. The Ketogenic Diet and Related Therapies in “Novel” Situations. Herausgegeben von Eric H. Kossoff. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.003.0008.

Der volle Inhalt der Quelle
Annotation:
The ketogenic diet (KD) is often considered as a treatment option for medication-resistant focal epilepsies and symptomatic generalized epilepsies, but is perhaps less commonly considered for idiopathic generalized epilepsies. The evidence for the use of the KD in two common idiopathic generalized epilepsy syndromes, childhood absence epilepsy and juvenile myoclonic epilepsy, is presented here.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
47

Demitrack, Mark A., und Sarah H. Lisanby. Methodological issues in clinical trial design for TMS. Herausgegeben von Charles M. Epstein, Eric M. Wassermann und Ulf Ziemann. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780198568926.013.0039.

Der volle Inhalt der Quelle
Annotation:
This article explores the emergence of transcranial magnetic stimulation (TMS) as a new therapeutic approach and the implications of this technology for the study and treatment of neuropsychiatric disorders, with a focus on major depression. Relapse, chronicity, and varying degrees of treatment resistance characterize major depression. A substantial number of patients are not effectively treated with pharmacology or medications alone. It is proposed that TMS, along with other device-based therapies emerging in psychiatry, may define a potential new treatment platform, with existing therapeutics for major depression. Through the example of a study, this article describes the methodological considerations in the development of TMS for the treatment of major depression. Device-based approaches to therapeutic neuromodulation hold the promise of significant clinical advantages compared to existing treatments for major depression, but evidence in well designed and properly blinded multicenter trials is still lacking, hence, research in this area is ongoing.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
48

Shapiro, Leslie J. Understanding OCD. ABC-CLIO, LLC, 2015. http://dx.doi.org/10.5040/9798216029649.

Der volle Inhalt der Quelle
Annotation:
One of the most experienced therapists in the world for treatment-resistant obsessive compulsive disorder (OCD) explains the disorder, the treatments available, and the skills needed to overcome and outsmart OCD. This is an eye-opening study of one of the most common psychiatric ailments diagnosed today—obsessive compulsive disorder (OCD). Written by Leslie J. Shapiro, a renowned therapist at one of the most well known OCD facilities in the world, this reference shares effective treatment strategies and clinical factors for helping therapists, mental health professionals, psychology students, clergy, and others deal with patients coping with this illness. The author offers case examples from her 15 years of residential work with patients, demonstrating how sufferers—even the most treatment resistant—can get control of the condition. Organized into three sections, this guidebook first reveals how OCD and guilt are intertwined and explores survival instincts, cultural factors, and the nature of thoughts. The second section covers aspects of the obsessive conscience such as scrupulosity, moralosity, and obsessive guilt. The book’s conclusion describes effective exposure and response prevention strategies for these symptoms and examines methods of treatment that augment and help maintain recovery. An in-depth discussion on the differences between compulsive and impulsive behaviors—as well as other treatment impediments—is included.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
49

Mukherji, Deborah, Aurelius Omlin, Carmel Pezaro und Johann De Bono. Novel therapies and emerging strategies for the treatment of patients with castration-resistant prostate cancer. Herausgegeben von James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0069.

Der volle Inhalt der Quelle
Annotation:
Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phase III studies for patients with metastatic CRPC. Furthermore, multiple agents and combinations are currently in late-stage clinical testing. Men with advanced prostate cancer represent an important population for clinical and translational research and clinical trial participation should be considered as part of standard care.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
50

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone und Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Der volle Inhalt der Quelle
Annotation:
There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie